Chemotherapy News and Research

Latest Chemotherapy News and Research

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

British researchers have discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics. The study has found that an abnormality on chromosome 17, called CEP17, is not only associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines. The research will be presented at the European Breast Cancer Conference (EBCC7) Thursday 25th March.

26 Mar 2010

Informing young women surviving breast cancer about opportunities to have children

At a time when more and more young women are surviving breast cancer and delaying childbirth, it is important to take their needs and wishes about their future fertility into consideration when deciding on treatment, the seventh European Breast Cancer Conference (EBCC7) in Barcelona will hear today.

26 Mar 2010

False perception of increased risk induces women with breast cancer have prophylactic mastectomies

Women who have been diagnosed with breast cancer believe the risk of the disease occurring in their unaffected breast is as much as ten times higher than it actually is. As a result, they are choosing to have prophylactic mastectomies based on a false perception of increased risk, according to new research.

26 Mar 2010

Adjuvant systemic must be considered for treatment of primary breast cancer and recurrence

Recurrence of breast cancer in the same area as the original tumour remains the strongest, independent prognostic factor for subsequent metastasis and death, even for patients who have been free of disease for a very long time, according to research presented today (Wednesday) at the seventh European Breast Cancer Conference (EBCC7).

26 Mar 2010

Bevacizumab/paclitaxel/carboplatin regimen attains gold-standard status for treatment of non-small-cell lung cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.

26 Mar 2010

Pregnant breast cancer patients can receive chemotherapy without endangering baby health

Women who discover they have breast cancer while they are pregnant can be treated with chemotherapy without endangering the health of their unborn baby, according to research to be presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday).

26 Mar 2010

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.

26 Mar 2010

AVASTIN receives Health Canada approval for patients with GBM

Roche Canada announced today that Health Canada has approved AVASTIN(R) (bevacizumab), as a single agent, for the treatment of patients with glioblastoma multiforme, the most aggressive primary malignant brain tumour, after relapse or disease progression, following prior therapy.

26 Mar 2010

Palex Medical to distribute Genomic Health's Oncotype DX breast cancer test in Spain and Portugal

Genomic Health, Inc. today announced that the company has entered into an exclusive agreement with Palex Medical S.A., one of Europe's leading distributors of medical device and diagnostic services to hospitals, to distribute its Oncotype DX® breast cancer test in Spain and Portugal. The distribution agreement, announced in conjunction with positive data presented today at the 7th European Breast Cancer Conference (EBCC), further expands the global presence of Oncotype DX, providing for increased physician and patient access to this advanced diagnostic test in the European market.

26 Mar 2010

JCOM receives approval from KFDA to commercialize MuGard in Korea

ACCESS PHARMACEUTICALS, INC. announced that JCOM Co., Ltd., its Korean licensee for both MuGard™ and ProLindac™, has received approval from the Korean Food and Drug Administration of its Registration Dossier for MuGard, an oncology supportive-care treatment for the management of oral mucositis.

26 Mar 2010

Scott & White seeks breast cancer patients for Phase II clinical trial

Scott & White Healthcare researchers are studying an investigational agent that targets metastatic breast cancer to find if it can stop cancer cells from continuing to grow.

25 Mar 2010

Colorectal cancer survivor shares her experience

For Hempstead resident Lynette Love, mother of four and grandmother of five, surviving colorectal cancer took courage, diligence and faith. Now a 3-year survivor, Love is giving the love back to the community through her participation in the Sprint for Colorectal Oncology Prevention and Education (SCOPE) run.

25 Mar 2010

Agendia brings new personalized treatment for breast cancer patients

Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor subtypes.

24 Mar 2010

Fertility remains a significant issue for majority of breast cancer patients

The use of chemotherapy and hormonal treatments in young women can have significant implications for their fertility.

24 Mar 2010

Gentium presents abstract on Defibrotide at EBMT Annual Meeting

Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.

24 Mar 2010

Bioalliance Pharma's anti-emetic drug Setofilm receives European approval

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced approval for Setofilm® in 16 European countries.

24 Mar 2010

Renowned leaders to discuss latest findings in early-stage drug development for cancer

When people think of cancer treatment, chemotherapy infusions, injections and pills often come to mind. These treatments result from extensive research and testing in drug development. But how does the process begin?

24 Mar 2010

Report shows growth of the U.S. market for vascular access devices and accessories

According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for vascular access devices and accessories was valued at just over $3 billion in 2009 and is estimated to reach over $4.6 billion by 2016.

23 Mar 2010

More awareness and earlier diagnosis of brain cancer needed

One of the UK’s largest surveys of brain cancer sufferers and carers, conducted by the Samantha Dickson Brain Tumour Trust, suggests that GPs and the general public need better guidance on spotting the key symptoms to aid earlier diagnosis and improve survival.

23 Mar 2010

ChemGenex shares falter as FDA requests more data on new leukemia drug

ChemGenex Pharmaceuticals Ltd. Shares fell most in the last 16 years to AUD$0.44 following a concern raised by the US drug regulators – US FDA. The FDA requested on Monday for more uniform clinical test data before they review and consider approval of the company’s new leukemia drug.

23 Mar 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

Informing young women surviving breast cancer about opportunities to have children

False perception of increased risk induces women with breast cancer have prophylactic mastectomies

Adjuvant systemic must be considered for treatment of primary breast cancer and recurrence

Bevacizumab/paclitaxel/carboplatin regimen attains gold-standard status for treatment of non-small-cell lung cancer

Pregnant breast cancer patients can receive chemotherapy without endangering baby health

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

AVASTIN receives Health Canada approval for patients with GBM

Palex Medical to distribute Genomic Health's Oncotype DX breast cancer test in Spain and Portugal

JCOM receives approval from KFDA to commercialize MuGard in Korea

Scott & White seeks breast cancer patients for Phase II clinical trial

Colorectal cancer survivor shares her experience

Agendia brings new personalized treatment for breast cancer patients

Fertility remains a significant issue for majority of breast cancer patients

Gentium presents abstract on Defibrotide at EBMT Annual Meeting

Bioalliance Pharma's anti-emetic drug Setofilm receives European approval

Renowned leaders to discuss latest findings in early-stage drug development for cancer

Report shows growth of the U.S. market for vascular access devices and accessories

More awareness and earlier diagnosis of brain cancer needed

ChemGenex shares falter as FDA requests more data on new leukemia drug

Cancer Research - Second Edition eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Newsletters you may be interested in